Abstract:ID 92395 Poster Board 511 Opioid Use Disorder (OUD) is a chronic, relapsing disease that, despite our best research efforts, has become a worsening public health crisis. Currently, the medications to treat OUD belong to the opioid class of drugs and, therefore, continue to interact directly with opioid receptors. While these medications are safe and effective for the cessation of opioids with higher abuse potentials, there is still a need for effective non-opioid receptor-targeting therapeutics. Exploring novel non-opioid targets is necessary to overcome this barrier. One such non-opioid target we are currently investigating is the calcitonin gene-related peptide (CGRP) system, particularly CGRP-expressing neurons in the parabrachial nucleus (CGRP PBN ). These neurons have been well studied in itch and pain and are known to project to brain regions implicated in opioid reward and withdrawal. Previous studies in our lab have found that CGRP PBN activity decreases during opioid taking and increases during opioid withdrawal. To further characterize the behavioral role of CGRP PBN neurons in opioid withdrawal, Calca-Cre transgenic mice received viral injections into the PBN containing an inhibitory DREADD (hm4Di), and two weeks later, mice were implanted with 2x25 mg morphine pellets. After five days, morphine withdrawal was induced by removing the pellets. Mice were administered either clozapine-N-oxide (CNO) (3 mg/kg, I.P.) or vehicle (saline, I.P.) 5.5 hours post pellet removal, and behavior was recorded at 6 and 24 hours post pellet removal. Two experimenters scored videos for jumping and wet dog shakes. Those mice injected with CNO showed fewer wet-dog shakes at the 6-hour time than vehicle-injected controls. We next sought to characterize the behavioral role of CGRP PBN neurons in opioid taking. In this experiment, morphine intravenous self-administration (IVSA) was used. Calca-Cre transgenic mice received viral injections into the PBN containing either an inhibitory DREADD (hm4Di) or a control mCherry vector and, two weeks later, were implanted with jugular catheters. Subsequently, operant responding for intravenous morphine was established. After 12 daily sessions, mice were administered CNO (3 mg/kg, I.P.) or vehicle (saline, I.P.) and allowed to respond for morphine. CGRP PBN inhibition reduced morphine intake in hm4Di-injected animals, while those with a control virus maintained their previous levels of morphine intake. Decreases in morphine intake were maintained 24 hours after CNO administration but returned to previous baseline levels at 48 hours. These results suggest that CGRP PBN neurons play a role in the behavioral consequences of both opioid reinforcement and withdrawal. CGRP receptor inhibitors are FDA-approved for the treatment of migraine and exist in both short and long-lasting formulations. By leveraging these available medications for the off-label purpose of treating OUD, we may be able to determine the translational potential of these preclinical findings and, therefore, expand our therapeutic arsenal for long-term maintenance of opioid abstinence and relapse.

Cell-type specific expression and behavioral impact of galanin and GalR1 in the locus coeruleus during opioid withdrawal

Galanin Receptor 1 Plays an Antinociceptive Effect Via Inhibiting PKA Activation in the Nucleus Accumbens of Rats with Neuropathic Pain

Oxycodone Withdrawal Induces HDAC1/HDAC2-dependent Transcriptional Maladaptations in the Reward Pathway in a Mouse Model of Peripheral Nerve Injury

An Interaction of Opioids and Galanin in Dorsal Horn of the Spinal Cord in Mononeuropathic Rats

Pannexin-1 channel inhibition alleviates opioid withdrawal in rodents by modulating locus coeruleus to spinal cord circuitry

Alternation of galanin in nociceptive modulation in the central nervous system of rats during morphine tolerance: a behavioral and immunohistochemical study.

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

Mu-Opioid Receptors Expressed in Glutamatergic Neurons Are Essential for Morphine Withdrawal.

The Role of TNF Α in the Periaqueductal Gray During Naloxone-Precipitated Morphine Withdrawal in Rats

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) As a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment

Inhibition of Parabrachial CGRP Neurons Reduces Morphine Reinforcement and Withdrawal

Receptor subtype-dependent galanin actions on gamma-aminobutyric acidergic neurotransmission and ethanol responses in the central amygdala

Interactions of galanin and opioids in nociceptive modulation in the arcuate nucleus of hypothalamus in rats.

Opioid-driven disruption of the septal complex reveals a role for neurotensin-expressing neurons in withdrawal

Involvement of Galanin and Galanin Receptor 1 in Nociceptive Modulation in the Central Nucleus of Amygdala in Normal and Neuropathic Rats.

Interactions of galanin and morphine in the spinal antinociception in rats with mononeuropathy

Astroglial Knockout of Glucocorticoid Receptor Attenuates Morphine Withdrawal Symptoms, but Not Antinociception and Tolerance in Mice

Effect of NR2B Antisense Oligonucleotide on Naloxone-Induced Withdrawal Responses in Morphine-Dependent Rats

Parvalbumin Interneurons of Central Amygdala Regulate the Negative Affective States and the Expression of Corticotrophin-Releasing Hormone During Morphine Withdrawal.

Galnon Facilitates Extinction of Morphine-Conditioned Place Preference but Also Potentiates the Consolidation Process.

Decreased myelin-related gene expression in the nucleus accumbens during spontaneous neonatal opioid withdrawal in the absence of long-term behavioral effects in adult outbred CFW mice